Spreadsheet showing Cervical screening: coverage by CCG and GP practice March 2019.
Executive summary of quality assurance (QA) visit to Canterbury held on 6 March 2019.
Executive summary of quality assurance (QA) visit to City, Sandwell & Walsall held on 18 March 2019.
Document published byThe Royal College of Anaesthetists, Macmillan Cancer Support, and the National Institute for Health Research (NIHR) Cancer and Nutrition Collaboration calling for changes to the delivery of cancer care across the UK, with a greater focus on prehabilitation
Technical evaluation of the IMS Giotto Class digital mammography system in 2D mode, used in the NHS breast screening programme. Thisreport is one of a series of technical reports evaluating commercially available mammography systems on behalf of the NHS breast
The NHS breast surveillance protocols for women at higher risk of developing breast cancer. Healthcare professionals working in the NHS breast screening programme should use these protocols. They apply to women referred to the screening programme with a higher risk of developing
Executive summary of quality assurance (QA) visit to South Lancashire Breast Screening Service, held on 13 March 2019.
Executive summary of quality assurance (QA) visit to Lancashire bowel cancer screening service, held on 28 and 29 November 2018.
This document collects findings from the quality assurance visit to Bristol and Weston, held on 15 and 16 January 2019. The visit evaluated the bowel cancer screening programme, and was conducted by the PHE screening quality assurance service (SQAS).
RAND Europe report that finds: Existing effective treatment for early breast cancer may lead policymakers and payers to underestimate the need for investment in further improvements and innovation in treatment and delivery of care in early breast cancer. The cost
The main curative treatment for patients with localised OG cancer is to remove the tumour with surgery (usually along with receiving chemotherapy or chemo-radiotherapy). As many OG patients are diagnosed with the condition at an advanced stage, only 30% of
The national dose banding tables are to be used by hospital trust pharmacy teams to ensure a standard approach to dose banding of chemotherapy across all hospital trusts.
Details, for the review of national cancer screening programmes in England.
This handbook contains tips from the five Faster Diagnosis Standard (FDS) test sites, who worked collaboratively with NHS England to: Robustly test and develop the rules for the faster diagnosis standard Explore impact on patients and the clinical services of
A series of papers brought together by the Thinktank Reform looking at the potential of a data-driven approach to cancer care. The articles show how data are currently shaping the delivery of cancer care, how to gain the most from
NHS England will not routinely commission 18F-FDG-PET CT as part of radical radiotherapy treatment planning for oesophageal cancer in accordance with the criteria outlined in this document. In creating this policy NHS England has reviewed this clinical condition and the
This report accepts that everyone should receive the care and support they need after a stem cell transplant, for as long as necessary and no matter where they live. But evidence shows that this is not always the case, which
This document clarifies the process of running failsafe batches to identify eligible women who have not been invited for screening. All breast screening services must specify and select routine failsafe batches monthly between day 13 and day 17 of every
Report that explores the feasibility of introducing one type of flexible payment mechanism –outcome-based payment (OBP) –for cancer medicines into the NHS in England. This model links the price the NHS pays for a medicine to the outcomes it achieves
Executive summary of quality assurance (QA) visit to West Devon and East Cornwall held on 25 September 2018.